SCHEDULE: Vanguard Amends Capricor Therapeutics Stake
Beneficial Ownership Report (Schedule 13G Amendment)
The Vanguard Group has filed an amendment to its Schedule 13G, disclosing a 4.82% beneficial ownership in Capricor Therapeutics Inc. common stock.
Summary
- The Vanguard Group reported beneficial ownership of 2,206,719 shares of Capricor Therapeutics Inc. common stock.
- This represents 4.82% of the total class of securities.
- Vanguard holds sole dispositive power over 1,927,572 shares and shared dispositive power over 279,147 shares.
- Vanguard holds shared voting power over 263,397 shares and no sole voting power.
- The filing is an Amendment No. 1 to a previously filed Schedule 13G.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine disclosure of institutional ownership and does not contain performance or strategic information about the issuer.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding institutional ownership, indicating The Vanguard Group's continued interest in the company's common stock.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement |
| 10/30/2025 | Signature date of the filing |
Keywords
Vanguard Group, Capricor Therapeutics, Schedule 13G, beneficial ownership, common stock, institutional ownership, investment adviser, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.